Marc C Chamberlain1. 1. University of Washington, Department of Neurology/Division of Neuro-Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, PO Box 19023, MS G4940, Seattle, WA 98109-1023, USA. chambemc@u.washington.edu.
Abstract
AIM: Quantify imaging abnormalities in a retrospective case series of patients with leptomeningeal metastasis (LM). METHODS: A total of 240 adult patients with LM (125 nonbrain solid tumor patients with positive cerebrospinal fluid [CSF] cytology; 40 nonbrain solid tumor patients with negative CSF cytology and positive MRI; and 50 lymphoma and 25 leukemia patients with positive CSF-flow cytometry) underwent brain and entire spine MRI and radioisotope CSF-flow studies prior to treatment. RESULTS: MRI was more often abnormal in solid tumors (40 CSF defined and 100% in MRI defined) compared with hematologic cancers (16-20%; p = 0.03). Similarly, CSF-flow studies was more often abnormal in solid tumors (25-28%) compared with hematologic cancers (10-20%; p = 0.04). MRI and flow-study abnormalities altered therapy in a third of solid tumors and 15% of hematologic cancers. CONCLUSION: Although imaging abnormalities are less often seen in hematologic cancers compared with solid tumor LM, imaging abnormalities frequently result in treatment alteration.
AIM: Quantify imaging abnormalities in a retrospective case series of patients with leptomeningeal metastasis (LM). METHODS: A total of 240 adult patients with LM (125 nonbrain solid tumorpatients with positive cerebrospinal fluid [CSF] cytology; 40 nonbrain solid tumorpatients with negative CSF cytology and positive MRI; and 50 lymphoma and 25 leukemiapatients with positive CSF-flow cytometry) underwent brain and entire spine MRI and radioisotope CSF-flow studies prior to treatment. RESULTS: MRI was more often abnormal in solid tumors (40 CSF defined and 100% in MRI defined) compared with hematologic cancers (16-20%; p = 0.03). Similarly, CSF-flow studies was more often abnormal in solid tumors (25-28%) compared with hematologic cancers (10-20%; p = 0.04). MRI and flow-study abnormalities altered therapy in a third of solid tumors and 15% of hematologic cancers. CONCLUSION: Although imaging abnormalities are less often seen in hematologic cancers compared with solid tumor LM, imaging abnormalities frequently result in treatment alteration.
Authors: Marc Chamberlain; Riccardo Soffietti; Jeffrey Raizer; Roberta Rudà; Dieta Brandsma; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Larry Junck; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle Journal: Neuro Oncol Date: 2014-05-27 Impact factor: 12.300
Authors: Marc Chamberlain; Larry Junck; Dieta Brandsma; Riccardo Soffietti; Roberta Rudà; Jeffrey Raizer; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Julie Walker; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Jacob J Mandel; Shlomit Yust-Katz; David Cachia; Jimin Wu; Diane Liu; John F de Groot; Alfred W K Yung; Mark R Gilbert Journal: J Neurooncol Date: 2014-08-29 Impact factor: 4.130
Authors: Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci Journal: Oncotarget Date: 2017-08-16
Authors: Mariano Montes de Oca Delgado; Bernardo Cacho Díaz; José Santos Zambrano; Vicente Guerrero Juárez; Manuel Salvador López Martínez; Elvira Castro Martínez; Javier Avendaño Méndez-Padilla; Sonia Mejía Pérez; Ignacio Reyes Moreno; Axayacatl Gutiérrez Aceves; Alberto González Aguilar Journal: Front Oncol Date: 2018-11-20 Impact factor: 6.244